Interleukin-33 alleviates the immunosuppressive tumor microenvironment and enhances anti-programmed death ligand-1 immunotherapy efficacy in hepatocellular carcinoma.

Authors

Ensi Ma, Yange Gu, Weiqiao He, Yunshu Ma, Shengran Jiang, Quanbao Zhang, Xiaomu Hu, Jing Zhao, Zhengxin Wang

Published in

Chinese medical journal. Sep 22, 2026. Epub Sep 22, 2026.

Abstract

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide. The immunosuppressive tumor microenvironment (TME) and limited response to immune checkpoint blockade (ICB) therapy remain major obstacles to improving HCC prognosis. Interleukin-33 (IL33) is a multifunctional cytokine that plays critical roles in cancer development; however, its function in HCC remains unclear.
Cell proliferation was evaluated using colony formation and 5-ethynyl-2'-deoxyuridine (EdU) staining assays. Tumor-bearing models were established in both immunocompetent and immunodeficient mice. Multiplex immunofluorescence and flow cytometry were performed to assess TME characteristics. RNA sequencing and Western blot analyses were conducted to investigate the underlying mechanisms.
We found that IL33 downregulation was significantly associated with shorter survival in patients with HCC. IL-33 treatment markedly inhibited tumor progression, whereas endogenous IL-33 blockade accelerated tumor growth in immunocompetent mice. However, IL-33 showed no significant effect on cell proliferation in vitro and failed to suppress tumor growth in immunodeficient mice lacking T cells. IL-33 administration notably reduced immunosuppressive tumor-associated macrophages and myeloid-derived suppressor cells, while substantially increasing CD8+ T cells, particularly functional interferon (IFN)-γ+CD8+ T cells, within the TME. Mechanistically, IL-33 activated the stimulator of interferon genes/interferon regulatory factor signaling axis, enhanced IFN-γ secretion, and inhibited RICTOR and programmed death 1 expression in mouse tumors. Furthermore, HCC specimens with high IL-33 expression exhibited more tertiary lymphoid structures. In addition, combined IL-33 and anti-programmed death ligand-1 therapy synergistically reduced tumor burden and further enhanced antitumor immunity in vivo.
These findings indicate that IL-33 alleviates immunosuppression and enhances ICB efficacy, providing novel insights into its role in HCC immunotherapy.

PMID:
42810855
Bibliographic data and abstract were imported from PubMed on 30 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.